How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ramipril-irbesartan.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ramipril + Irbesartan — Competitive Intelligence Brief

Ramipril + Irbesartan (Ramipril + Irbesartan) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor + Angiotensin II receptor blocker combination. Area: Cardiovascular.

marketed ACE inhibitor + Angiotensin II receptor blocker combination ACE enzyme and AT1 angiotensin II receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Ramipril + Irbesartan (Ramipril + Irbesartan) — Bristol-Myers Squibb. This combination lowers blood pressure by blocking angiotensin II through two complementary pathways: ACE inhibition and angiotensin II receptor antagonism.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ramipril + Irbesartan TARGET	Ramipril + Irbesartan	Bristol-Myers Squibb	marketed	ACE inhibitor + Angiotensin II receptor blocker combination	ACE enzyme and AT1 angiotensin II receptor
Quinapril + Losartan	Quinapril + Losartan	AHEPA University Hospital	marketed	ACE inhibitor + Angiotensin II receptor blocker combination	Angiotensin-converting enzyme (ACE) and Angiotensin II type 1 receptor (AT1R)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor + Angiotensin II receptor blocker combination class)

AHEPA University Hospital · 1 drug in this class
Bristol-Myers Squibb · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ramipril + Irbesartan — Competitive Intelligence Brief. https://druglandscape.com/ci/ramipril-irbesartan. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab